Kerstin Dolph’s Post

Learn more about the transformative potential of biobetters in this recent article featuring Ulrike Herbrand, PhD: https://okt.to/x5saW3

Learn more about the transformative potential of biobetters in this recent article featuring Ulrike Herbrand, PhD: https://okt.to/fdMHKX

Learn more about the transformative potential of biobetters in this recent article featuring Ulrike Herbrand, PhD: https://okt.to/pVAtMg

Learn more about the transformative potential of biobetters in this recent article featuring Ulrike Herbrand, PhD: https://okt.to/FztI3u

Learn more about the transformative potential of biobetters in this recent article featuring Ulrike Herbrand, PhD: https://okt.to/t0sAgk

SMALL MOLECULE renaissance in 2023 Let's unpack the statement.... (i) Highly innovative, vertical small molecule technologies are maturing e.g. protein degraders (ii) Drugging the undruggable is becoming reality, with regulatory drug case studies (iii) Biopharma and Advanced Therapies have left in their wake a whole range of new druggable, undruggable targets and market opportunities (iv) Innovative small molecules are fast becoming the new disruptors (v) There is visible convergence between technologies e.g. ADCs (vi) Data Strategy and Quantitative Science is delivering new discovery targets, new models, new higher standards of quality (vii) Large pharma are increasingly dialing up their scientific policies, toolkits and capabilities (viii) Unmet rare diseases and new orphan drugs are becoming within reach (ix) Small molecules cross boundaries that disallow their larger cousins (x) etc etc... Seize the moment! #smallmolecules, #smallmolecule, #drugdiscovery, #drugdevelopment, #drugsafety, #drugdelivery, #medicinalchemistry #regulatoryaffairs #targetedproteindegradation #TPD #molecularglues #biopharma #biopharmaceuticals #biopharmaceutical

👋🏼 Hello toxicologists! We presented at #SOT2024 new data produced by our high-content screening system SydLab™ One for #DART The study highlights the strong advantages of SydLab™ One: 📊 Reproducible and accurate results thanks to standardized protocols 🧪 An automated dosing of chemicals with low liquid consumption  🚀 Multi-phenotypic readouts in real-time in full organisms 🔬 Fully automated high-content screening platform = unlocking #Celegans model as a new #NAMs technology for #EarlyTox SydLab™ One represents the first all-in-one C. elegans microfluidic #labdevice that contributes to the rapid identification of toxic compounds de-risking and accelerating the early stages of discovery pipelines. Missed our presentation? Download the poster here 🔗👉🏼 https://lnkd.in/eVDeJ5rz #toxicology #ReproTox #stressresponse #fluorescence #labtechnology #microfluidics #OoC #HCS #labautomation #AIanalysis

Scientific innovation is bringing some exciting changes to the industry. For senior principal scientist John Cook, there’s one that he’s particularly excited about. “The acceptance of single well analysis for ligand binding assay (LBA) approaches. in the ICH M10 document should help to provide industry with greater confidence in single well analysis and as a result see increased adoption of this strategy. The use of single well analysis offers multiple benefits, such as reduction in volumes critical materials required for analysis and lower sample volumes from animals or patients. “ Learn more about what John and our bioanalysis experts have to offer: https://okt.to/1GqF6L

"With the right design you can do fewer experiments and end up with the same results." Marie GERUS-DURAND explains how moving from one-factor-at-a-time experiments to modern multifactor DOE significantly accelerated the development of clinical trial protocols. At Cerba Research, this shift has enabled faster, high-quality results for clients. Learn more about how DOE can optimize processes: https://go.jmp/3XSADVg #JMP #TimeToInnovate #ClinicalTrials #pharma #designofexperiments

Today is 𝗪𝗢𝗥𝗟𝗗 𝗟𝗔𝗕𝗢𝗥𝗔𝗧𝗢𝗥𝗬 𝗗𝗔𝗬 or, in other words, a day to highlight the importance of the epicenters of scientific discovery and innovation.  As a scientist, I spent much time in different laboratories in different countries and cities. Being in a lab is like being in a different world with countless different types of research, from healthcare advancements and disease diagnosis to groundbreaking research that paves the way for a better future, including fundamental research that helps understand and answer key questions. They are the engines driving progress, and not only the labs themselves, but the dedicated scientists within them deserve our recognition. By supporting laboratories and their research, we invest in a healthier tomorrow. Research leads to new medicines, technologies, 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 in general, and to a deeper understanding of the world around us. Every breakthrough starts in a lab! For this reason, I'm happy to be part of Biosynth, a company built around its customers. Whether you're in academia, a leading industry player, a biotech pioneer, a dedicated SME, or a scientist 👨🔬👩🔬 overall, we've got you covered. Our comprehensive offering includes everything you need for uninterrupted research, from essential products to invaluable services. Biosynth is your trusted partner, your one-stop-shop to avoid supply chain disruptions and focus on what matters most – 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗲𝘀! 🧪⚗️🧫 ➡ https://www.biosynth.com